{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:10:55Z","timestamp":1783948255306,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Neonatal diabetes mellitus (NDM) is a rare genetic disease characterized by severe hyperglycemia requiring insulin therapy with onset mostly within the first 6 months and rarely between 6-12 months of age. The disease can be classified into transient (TNDM) or permanent neonatal diabetes mellitus (PNDM), or it can be a component of a syndrome. The most frequent genetic causes are abnormalities of the 6q24 chromosomal region and mutations of the ABCC8 or KCNJ11 genes coding for the pancreatic beta cell\u2019s potassium channel (KATP). After the acute phase, patients with ABCC8 or KCNJ11 mutations treated with insulin therapy can switch to hypoglycemic sulfonylureas (SU). These drugs close the KATP channel binding the SUR1 subunit of the potassium channel and restoring insulin secretion after a meal. The timing of this switch can be different and could affect long-term complications. We describe the different management and clinical outcome over the time of two male patients with NDM due to KCNJ11 pathogenetic variants. In both cases, continuous subcutaneous insulin infusion pumps (CSII) were used to switch therapy from insulin to SU, but at different times after the onset. The two patients kept adequate metabolic control after the introduction of glibenclamide; during the treatment, insulin secretion was evaluated with c-peptide, fructosamine, and glycated hemoglobin (HbA1c), which were within the normal range. In neonates or infants with diabetes mellitus, genetic testing is an indispensable diagnostic tool and KCNJ11 variants should be considered. A trial of oral glibenclamide must be considered, switching from insulin, the first line of NDM treatment. This therapy can improve neurological and neuropsychological outcomes, in particular in the case of earlier treatment initiation. A new modified protocol with glibenclamide administered several times daily according to continuous glucose monitoring profile indications, was used. Patients treated with glibenclamide maintain good metabolic control and prevent hypoglycemia, neurological damage, and apoptosis of beta cells during long\u2010term administration.<\/jats:p>","DOI":"10.3389\/fendo.2023.1143736","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T14:13:01Z","timestamp":1683814381000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants"],"prefix":"10.3389","volume":"14","author":[{"given":"Valentina","family":"Mancioppi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Zanetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Missineo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Savastio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Barbetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Mellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Rabbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/PEDI.13426","article-title":"ISPAD clinical practice consensus guidelines 2022: the diagnosis and management of monogenic diabetes in children and adolescents","volume":"23","author":"Greeley","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/PEDI.12772","article-title":"ISPAD clinical practice consensus guidelines 2018: the diagnosis and management of monogenic diabetes in children and adolescents","volume":"19","author":"Hattersley","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S198932","article-title":"Recent advances in neonatal diabetes","volume":"13","author":"Dahl","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/S00592-021-01788-6","article-title":"Genetic and clinical heterogeneity of permanent neonatal diabetes mellitus: a single tertiary centre experience","volume":"58","author":"Laimon","year":"2021","journal-title":"Acta Diabetol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/J.CLP.2017.10.006","article-title":"Neonatal diabetes mellitus: an update on diagnosis and management","volume":"45","author":"Lemelman","year":"2018","journal-title":"Clin Perinatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/PEDI.13390","article-title":"Clinical presentation and long-term outcome of patients with KCNJ11\/ABCC8 variants: neonatal diabetes or MODY in the DPV registry from Germany and Austria","volume":"23","author":"Warncke","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/S00592-011-0331-8","article-title":"Minimal incidence of neonatal\/infancy onset diabetes in Italy is 1:90,000 live births","volume":"49","author":"Iafusco","year":"2012","journal-title":"Acta Diabetol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/S00592-015-0828-7","article-title":"Successful treatment of young infants presenting neonatal diabetes mellitus with continuous subcutaneous insulin infusion before genetic diagnosis","volume":"53","author":"Rabbone","year":"2016","journal-title":"Acta Diabetol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-1030","article-title":"Differences between transient neonatal diabetes mellitus subtypes can guide diagnosis and therapy","volume":"184","author":"Bonfanti","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4274\/JCRPE.5166","article-title":"A novel KCNJ11 mutation associated with transient neonatal diabetes","volume":"10","author":"Gole","year":"2018","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/DME.14728","article-title":"Neonatal diabetes caused by disrupted pancreatic and \u03b2-cell development","volume":"38","author":"de Franco","year":"2021","journal-title":"Diabetes Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/S13643-016-0369-3","article-title":"Incidence, prevalence and genetic determinants of neonatal diabetes mellitus: a systematic review and meta-analysis protocol","volume":"5","author":"Nansseu","year":"2016","journal-title":"Syst Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/FPED.2020.540718","article-title":"Neonatal diabetes mellitus","volume":"8","author":"Beltrand","year":"2020","journal-title":"Front Pediatr"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA032922","article-title":"Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes","volume":"350","author":"Gloyn","year":"2004","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA055068","article-title":"Activating mutations in the ABCC8 gene in neonatal diabetes mellitus","volume":"355","author":"Babenko","year":"2006","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1086\/519174","article-title":"Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects","volume":"81","author":"Ellard","year":"2007","journal-title":"Am J Hum Genet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/SJ.EJHG.5201629","article-title":"KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features","volume":"14","author":"Gloyn","year":"2006","journal-title":"Eur J Hum Genet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/SCIENCE.1186146","article-title":"Muscle dysfunction caused by a KATP channel mutation in neonatal diabetes is neuronal in origin","volume":"329","author":"Clark","year":"2010","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/S41574-020-0351-Y","article-title":"New insights into KATP channel gene mutations and neonatal diabetes mellitus","volume":"16","author":"Pipatpolkai","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/J.DIABRES.2017.04.007","article-title":"Insulin therapy in neonatal diabetes mellitus: a review of the literature","volume":"129","author":"Rabbone","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/PEDI.13376","article-title":"Sulfonylurea for improving neurological features in neonatal diabetes: a systematic review and meta-analyses","volume":"23","author":"de Gouveia Buff Passone","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2004-1241","article-title":"Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2","volume":"89","author":"Zung","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.6065\/APEM.2018.23.3.154","article-title":"Successful switching from insulin to sulfonylurea in a 3-month-old infant with diabetes due to p.G53D mutation in KCNJ11","volume":"23","author":"Yoon","year":"2018","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-1785","article-title":"Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations","volume":"31","author":"Rafiq","year":"2008","journal-title":"Diabetes Care"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13041","article-title":"Neonatal diabetes due to potassium channel mutation: response to sulfonylurea according to the genotype","volume":"21","author":"Garcin","year":"2020","journal-title":"Pediatr Diabetes"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.727083","article-title":"Molecular genetics, clinical characteristics, and treatment outcomes of KATP-channel neonatal diabetes mellitus in Vietnam national children\u2019s hospital","volume":"12","author":"Ngoc","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12823","article-title":"Glibenclamide oral suspension: suitable and effective in patients with neonatal diabetes","volume":"20","author":"Beltrand","year":"2019","journal-title":"Pediatr Diabetes"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2007-1826","article-title":"The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy","volume":"93","author":"Koster","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/PEDI.13406","article-title":"ISPAD clinical practice consensus guidelines 2022: diabetic ketoacidosis and hyperglycemic hyperosmolar state","volume":"23","author":"Glaser","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/S00125-006-0246-Z","article-title":"Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype","volume":"49","author":"Flanagan","year":"2006","journal-title":"Diabetologia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/DME.13575","article-title":"Sulfonylurea vs insulin therapy in individuals with sulfonylurea-sensitive permanent neonatal diabetes mellitus, attributable to a KCNJ11 mutation, and poor glycaemic control","volume":"35","author":"Stanik","year":"2018","journal-title":"Diabetes Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30106-2","article-title":"Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study","volume":"6","author":"Bowman","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0134476","article-title":"Systemic administration of glibenclamide fails to achieve therapeutic levels in the brain and cerebrospinal fluid of rodents","volume":"10","author":"Lahmann","year":"2015","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2014-2494","article-title":"Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons","volume":"99","author":"Carmody","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/S41431-019-0371-Z","article-title":"Precision medicine for a man presented with diabetes at 2-month old","volume":"27","author":"Ang","year":"2019","journal-title":"Eur J Hum Genet"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1143736\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T14:13:05Z","timestamp":1683814385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1143736\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":35,"alternative-id":["10.3389\/fendo.2023.1143736"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1143736","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"article-number":"1143736"}}